A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens

Christopher L. Yankaskas, Keyata N. Thompson, Colin D. Paul, Michele I. Vitolo, Panagiotis Mistriotis, Ankit Mahendra, Vivek K. Bajpai, Daniel J. Shea, Kristen M. Manto, Andreas C. Chai, Navin Varadarajan, Aikaterini Kontrogianni-Konstantopoulos, Stuart S. Martin, K Konstantopoulos

Research output: Contribution to journalArticle

Abstract

The challenge of predicting which patients with breast cancer will develop metastases leads to the overtreatment of patients with benign disease and to the inadequate treatment of aggressive cancers. Here, we report the development and testing of a microfluidic assay that quantifies the abundance and proliferative index of migratory cells in breast cancer specimens, for the assessment of their metastatic propensity and for the rapid screening of potential antimetastatic therapeutics. On the basis of the key roles of cell motility and proliferation in cancer metastasis, the device accurately predicts the metastatic potential of breast cancer cell lines and of patient-derived xenografts. Compared with unsorted cancer cells, highly motile cells isolated by the device exhibited similar tumourigenic potential but markedly increased metastatic propensity in vivo. RNA sequencing of the highly motile cells revealed an enrichment of motility-related and survival-related genes. The approach might be developed into a companion assay for the prediction of metastasis in patients and for the selection of effective therapeutic regimens.

Original languageEnglish (US)
JournalNature biomedical engineering
DOIs
StatePublished - Jan 1 2019

Fingerprint

Microfluidics
Assays
Cells
Breast Neoplasms
Neoplasm Metastasis
RNA
Heterografts
Screening
Genes
RNA Sequence Analysis
Equipment and Supplies
Neoplasms
Testing
Patient Selection
Cell Movement
Therapeutics
Cell Proliferation
Cell Line
Survival

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Computer Science Applications

Cite this

A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens. / Yankaskas, Christopher L.; Thompson, Keyata N.; Paul, Colin D.; Vitolo, Michele I.; Mistriotis, Panagiotis; Mahendra, Ankit; Bajpai, Vivek K.; Shea, Daniel J.; Manto, Kristen M.; Chai, Andreas C.; Varadarajan, Navin; Kontrogianni-Konstantopoulos, Aikaterini; Martin, Stuart S.; Konstantopoulos, K.

In: Nature biomedical engineering, 01.01.2019.

Research output: Contribution to journalArticle

Yankaskas, CL, Thompson, KN, Paul, CD, Vitolo, MI, Mistriotis, P, Mahendra, A, Bajpai, VK, Shea, DJ, Manto, KM, Chai, AC, Varadarajan, N, Kontrogianni-Konstantopoulos, A, Martin, SS & Konstantopoulos, K 2019, 'A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens', Nature biomedical engineering. https://doi.org/10.1038/s41551-019-0400-9
Yankaskas, Christopher L. ; Thompson, Keyata N. ; Paul, Colin D. ; Vitolo, Michele I. ; Mistriotis, Panagiotis ; Mahendra, Ankit ; Bajpai, Vivek K. ; Shea, Daniel J. ; Manto, Kristen M. ; Chai, Andreas C. ; Varadarajan, Navin ; Kontrogianni-Konstantopoulos, Aikaterini ; Martin, Stuart S. ; Konstantopoulos, K. / A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens. In: Nature biomedical engineering. 2019.
@article{c226b4c6837e4bec90f82c3eac429105,
title = "A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens",
abstract = "The challenge of predicting which patients with breast cancer will develop metastases leads to the overtreatment of patients with benign disease and to the inadequate treatment of aggressive cancers. Here, we report the development and testing of a microfluidic assay that quantifies the abundance and proliferative index of migratory cells in breast cancer specimens, for the assessment of their metastatic propensity and for the rapid screening of potential antimetastatic therapeutics. On the basis of the key roles of cell motility and proliferation in cancer metastasis, the device accurately predicts the metastatic potential of breast cancer cell lines and of patient-derived xenografts. Compared with unsorted cancer cells, highly motile cells isolated by the device exhibited similar tumourigenic potential but markedly increased metastatic propensity in vivo. RNA sequencing of the highly motile cells revealed an enrichment of motility-related and survival-related genes. The approach might be developed into a companion assay for the prediction of metastasis in patients and for the selection of effective therapeutic regimens.",
author = "Yankaskas, {Christopher L.} and Thompson, {Keyata N.} and Paul, {Colin D.} and Vitolo, {Michele I.} and Panagiotis Mistriotis and Ankit Mahendra and Bajpai, {Vivek K.} and Shea, {Daniel J.} and Manto, {Kristen M.} and Chai, {Andreas C.} and Navin Varadarajan and Aikaterini Kontrogianni-Konstantopoulos and Martin, {Stuart S.} and K Konstantopoulos",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41551-019-0400-9",
language = "English (US)",
journal = "Nature Biomedical Engineering",
issn = "2157-846X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens

AU - Yankaskas, Christopher L.

AU - Thompson, Keyata N.

AU - Paul, Colin D.

AU - Vitolo, Michele I.

AU - Mistriotis, Panagiotis

AU - Mahendra, Ankit

AU - Bajpai, Vivek K.

AU - Shea, Daniel J.

AU - Manto, Kristen M.

AU - Chai, Andreas C.

AU - Varadarajan, Navin

AU - Kontrogianni-Konstantopoulos, Aikaterini

AU - Martin, Stuart S.

AU - Konstantopoulos, K

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The challenge of predicting which patients with breast cancer will develop metastases leads to the overtreatment of patients with benign disease and to the inadequate treatment of aggressive cancers. Here, we report the development and testing of a microfluidic assay that quantifies the abundance and proliferative index of migratory cells in breast cancer specimens, for the assessment of their metastatic propensity and for the rapid screening of potential antimetastatic therapeutics. On the basis of the key roles of cell motility and proliferation in cancer metastasis, the device accurately predicts the metastatic potential of breast cancer cell lines and of patient-derived xenografts. Compared with unsorted cancer cells, highly motile cells isolated by the device exhibited similar tumourigenic potential but markedly increased metastatic propensity in vivo. RNA sequencing of the highly motile cells revealed an enrichment of motility-related and survival-related genes. The approach might be developed into a companion assay for the prediction of metastasis in patients and for the selection of effective therapeutic regimens.

AB - The challenge of predicting which patients with breast cancer will develop metastases leads to the overtreatment of patients with benign disease and to the inadequate treatment of aggressive cancers. Here, we report the development and testing of a microfluidic assay that quantifies the abundance and proliferative index of migratory cells in breast cancer specimens, for the assessment of their metastatic propensity and for the rapid screening of potential antimetastatic therapeutics. On the basis of the key roles of cell motility and proliferation in cancer metastasis, the device accurately predicts the metastatic potential of breast cancer cell lines and of patient-derived xenografts. Compared with unsorted cancer cells, highly motile cells isolated by the device exhibited similar tumourigenic potential but markedly increased metastatic propensity in vivo. RNA sequencing of the highly motile cells revealed an enrichment of motility-related and survival-related genes. The approach might be developed into a companion assay for the prediction of metastasis in patients and for the selection of effective therapeutic regimens.

UR - http://www.scopus.com/inward/record.url?scp=85065324254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065324254&partnerID=8YFLogxK

U2 - 10.1038/s41551-019-0400-9

DO - 10.1038/s41551-019-0400-9

M3 - Article

C2 - 31061459

AN - SCOPUS:85065324254

JO - Nature Biomedical Engineering

JF - Nature Biomedical Engineering

SN - 2157-846X

ER -